NCT06947330

Brief Summary

The goal of this clinical trial is to compare Ultrasound Guided Erector Spinae and Ultrasound Guided Serratus Anterior Plane Block post Modified Radical Mastectomy in adult females. the main questions it aims to answer are:

  • Which of the two blocks has a better analgesic effect?
  • Which of the two blocks is safer as regards inducing a pneumothorax and affecting the hemodynamics? Participants:
  • Will be divided into two groups after signing the informed consent.
  • After being anesthetized and before surgical incision; the blocks will be given to the patient.
  • Lung Ultrasound will be done for each patient to rule out pnemothorax once before the surgery and another after the end of surgery while the patient is being anesthetized.
  • Patients that will experience pneuomothorax will be excluded from the study, and will be treated according to its size.
  • Follow up of the patient for 24 hours postoperative to record the VAS score continuously, with giving increments of pethidine intravenously to relief pain.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2025

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 3, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 13, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 27, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2026

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 4, 2026

Completed
Last Updated

April 27, 2025

Status Verified

April 1, 2025

Enrollment Period

1 year

First QC Date

April 13, 2025

Last Update Submit

April 20, 2025

Conditions

Keywords

Breast CancerModified Radical MastectomyPeripheral Nerve BlockDexmedetomidineErector Spinae Plane BlockSerratus Anterior Plane BlockUltrasound GuidedAdult Female

Outcome Measures

Primary Outcomes (1)

  • Visual Analog Score for pain

    * After extubation, the patient will be discharged from the operating room. VAS will be used to assess the postoperative pain (Myles et al., 2017). * Visual analogue scale score: Grade 0 (0-1 units on a scale): Good analgesia. Grade I (2-4 units on a scale): Moderate analgesia Grade II (5-7 units on a scale): Mild analgesia Grade III (8-10 units on a scale): No analgesia. * If VAS \>3 units on a scale postoperatively, IV increment of pethidine 30 mg diluted in 5 ml saline will be given. * VAS ranging from (0 units on a scale) no pain, to (10 units on a scale) severe intolerable pain;

    at 0, 2, 4, 6, 8, 16, 20, 24 hours postoperatively

Secondary Outcomes (4)

  • Total dose of pethidine in mg.

    at 0, 2, 4, 6, 8, 16, 20, 24 hours postoperatively

  • Duration of analgesia postoperatively in hours.

    at 0, 2, 4, 6, 8, 16, 20, 24 hours postoperatively

  • Rate of vital data changes over the postoperative period

    every 2 hour during the first 6 hours and then every 6 hours for 24 hours postoperatively.

  • Incidence of pneumothorax

    Intra-operatively

Study Arms (2)

Unilateral Erector Spinae group

ACTIVE COMPARATOR

-The patient will be turned to the lateral decubitus position and the surgical side superiorly. After proper sterilization; The linear probe will be put in a parasagittal plane over the transverse process of thoracic 4 or thoracic 5 vertebrae, approximately 2.5 cm lateral to the spinous processes. The transverse process has a square form contour as compared to the rib which is rounded form contour. Then the 3 muscle layers or sheets with facial plane are distinguished from superficial to deep as trapezius, rhomboid major, and erector spinae with flickering pleura in between the transverse processes. The block will be managed unilaterally by in-plane technique using 22-gauge, 50 mm, echogenic needle which will be inserted in a cranial-caudal orientation and the block needle will be proceeded through the trapezius, rhomboid major, and erector spinae to smoothly contact the transverse process. Needle location will be confirmed by hydro-dissection on injecting 2-3 ml normal saline.

Procedure: Unilateral Erector Spinae group

Unilateral Serratus Anterior group

ACTIVE COMPARATOR

-After skin sterilization, with the patient in the lateral decubitus position and the side of surgery superiorly, the ultrasound linear probe will be put longitudinally oblique just below the mid-clavicle. After distinguish the second rib, the probe will be mobilized caudally and laterally (obliquely), towards the mid-axillary line to distinguish the third, fourth and fifth ribs. The ideal and definite probe position has its cephalad end at the anterior axillary line and the caudal end at the posterior axillary line. The facial plane between the serratus anterior muscle and ribs four and five will be identified between the 4th and 5th rib in the mid-axillary region. Under sonar guided, 50 mm echogenic needle will be advanced in-plane to introduce this facial plane in cranio-caudal direction.

Procedure: Unilateral Serratus Anterior group

Interventions

On injecting 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine into the interfacial plane below erector spinae; a manifest linear pattern will be visualized uplifting the muscle.

Also known as: Peripheral Nerve Block using Precedex, Erector Spinae block with Precedex as an adjuvant drug
Unilateral Erector Spinae group

Once the needle will be in perfect position, confirmed by hydro-dissection on injecting 2-3 ml of normal saline, then 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine.

Also known as: Peripheral Nerve Block using dexmedetomidine, Serratus Anterior Block with dexmedetomidine as an adjuvant drug
Unilateral Serratus Anterior group

Eligibility Criteria

Age21 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA Physical Status II, or III.
  • Age 21 - 65 years.
  • Female gender

You may not qualify if:

  • ASA IV, V, VI.
  • Infection at site of block.
  • Coagulopathy, or patients on antiplatelets, or anticoagulants.
  • Previous anesthetic allergy to bupivacaine.
  • Distant organ metastasis.
  • Male gender.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine, Ain-Shams University

Cairo, Waili, 0000, Egypt

RECRUITING

Related Publications (2)

  • Chen Z, Liu Z, Feng C, Jin Y, Zhao X. Dexmedetomidine as an Adjuvant in Peripheral Nerve Block. Drug Des Devel Ther. 2023 May 17;17:1463-1484. doi: 10.2147/DDDT.S405294. eCollection 2023.

    PMID: 37220544BACKGROUND
  • Abd Elmohsen Bedewy A, Mohamed MS, Sultan HM, Khalil MS. Comparison Between Erector Spinae Plane Block versus Serratus Anterior Plane Block Regarding Analgesia and Stress Response After Modified Radical Mastectomy: Randomized Controlled Trial. Anesth Pain Med. 2024 Mar 26;14(2):e142189. doi: 10.5812/aapm-142189. eCollection 2024 Apr.

    PMID: 38741901BACKGROUND

Related Links

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Sampling method will be simple random. Patients will be randomly assigned into one of the following groups using opaque sealed envelopes: 1. Group A (50 patients); will receive ultrasound guided Erector Spinae Plane Block. 2. Group B (50 patients); will receive ultrasound guided Serratus Anterior Plane Block.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

April 13, 2025

First Posted

April 27, 2025

Study Start

March 3, 2025

Primary Completion

March 3, 2026

Study Completion

March 4, 2026

Last Updated

April 27, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Available IPD Datasets

Study Protocol Access

Locations